Clinical Trial Update: A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis [Phase 1, Phase 2]

View source ↗

Summary

A long-term Phase 1/2 clinical trial evaluating orally administered SAR302503 in patients with Myelofibrosis has completed, sponsored by Bristol-Myers Squibb.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• SAR302503

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Myelofibrosis | Phase 1, Phase 2 | Status: COMPLETED